Home › Funds › Soleus Capital Management, L.P. › TRVI

Soleus Capital Management, L.P. position in TRVI

TREVI THERAPEUTICS INC · Health Care

Soleus Capital Management, L.P. reported holding 1,179,618 shares of TRVI (TREVI THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$22.0M, representing 0.76% of its reported portfolio and ranking #38 among its reported holdings. Soleus Capital Management, L.P. has disclosed TRVI holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)1.18M sh
Reported value held$22.00M
Portfolio Weight0.76%
First reportedQ2 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s TRVI position evolved

Soleus Capital Management, L.P. first disclosed a stake in TRVI in Q2 2025 at 700,000 shares (US$3.8M). The position peaked in Q2 2026 at 1,179,618 shares, worth US$22.0M. Across 5 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,179,618 shares valued at US$22.0M — a reduction of -440,382 shares quarter over quarter.. Notable position changes include a 96% trim in Q3 2025 (shares rose 37% over the following quarter), a 3500% increase in Q4 2025 (shares fell 5% over the following quarter), a 80% increase in Q1 2026 (shares rose 56% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 700.00K $3.83M New
Q3 2025 25.00K $228.75K Reduce
Q4 2025 900.00K $11.27M Add
Q1 2026 1.62M $19.33M Add
Q2 2026 1.18M $22.00M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRVI and 13F data

TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$95.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRVI

All TRVI fund holders →

FAQ

How long has Soleus Capital Management, L.P. held TRVI?

Soleus Capital Management, L.P. has disclosed TRVI holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Soleus Capital Management, L.P.'s current position in TRVI?

As of Q2 2026, Soleus Capital Management, L.P. holds 1.18M shares of TRVI (TREVI THERAPEUTICS INC), valued at $22.00M, representing 0.76% of its reported portfolio and ranking #38.

Has Soleus Capital Management, L.P. been buying or selling TRVI?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. reduced its position in TRVI. The position peaked in Q2 2026 at 1.18M shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 64 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.